Journey Medical's Emrosi Demonstrates Efficacy in Phase 3 Rosacea Trials Despite Weight Variance, Analysts Forecast 53.54% Upside.

Journey Medical's Emrosi has demonstrated superior efficacy in treating moderate-to-severe papulopustular rosacea in adults, according to Phase 3 clinical trial results. The treatment was well-tolerated and unaffected by variations in body weight among participants. Emrosi's FDA approval in November 2024 was reinforced by the findings. Wall Street analysts forecast an average target price of $9.75, with an upside of 53.54% from the current price of $6.35.

Journey Medical Corporation (Nasdaq: DERM) has announced the presentation of Phase 3 trial data for Emrosi™, an FDA-approved treatment for moderate-to-severe papulopustular rosacea, at the 2025 Summer Dermatology Conference. The data analysis from two Phase 3 clinical trials, Minocycline Versus Oracea in Rosacea-1 (MVOR-1) and Minocycline Versus Oracea in Rosacea-2 (MVOR-2), demonstrated that Emrosi's efficacy is independent of body weight. This finding simplifies prescribing and enhances its potential for market adoption.

The trial results, presented by Julie Harper, MD, past president of the American Acne & Rosacea Society (AARS), showed that Emrosi outperformed both placebo and doxycycline on primary endpoints, including Investigator’s Global Assessment (IGA) treatment success and reductions in total inflammatory lesion counts. The analysis included sub-group analyses based on body weight, confirming Emrosi's body weight-independent formulation.

Emrosi's FDA approval in November 2024 was further validated by these results, positioning it as a leading treatment option for rosacea management. The treatment's positive safety profile and well-tolerated nature may increase confidence among prescribing physicians and patients, facilitating broader market acceptance.

Wall Street analysts have issued a "Buy" rating on DERM stock, with an average target price of $9.75, representing an upside of 53.54% from the current price of $6.35. The stock has seen significant insider trading activity, with 10 sales and no purchases in the past six months. Additionally, 22 institutional investors added shares to their portfolios, while 19 decreased their positions in the most recent quarter.

References:
[1] https://www.nasdaq.com/articles/journey-medical-corporation-present-phase-3-data-emrositm-rosacea-2025-sdpa-summer